Core Viewpoint - The stock price of Kexing Pharmaceutical has shown significant volatility, with a year-to-date increase of 92.87%, but recent declines in the short term indicate potential market fluctuations [2]. Group 1: Stock Performance - As of September 19, Kexing Pharmaceutical's stock price rose by 2.02% to 42.01 CNY per share, with a trading volume of 1.42 billion CNY and a turnover rate of 1.69%, resulting in a total market capitalization of 8.455 billion CNY [1]. - The stock has experienced a decline of 1.18% over the last five trading days and a 5.60% drop over the past 20 days, while it has increased by 9.40% over the last 60 days [2]. Group 2: Company Overview - Kexing Pharmaceutical, established on August 22, 1997, is located in Jinan, Shandong Province, and specializes in the research, production, and sales of recombinant protein drugs and micro-ecological preparations, with 97.38% of its revenue coming from pharmaceutical products [3]. - The company has appeared on the stock market's "Dragon and Tiger List" six times this year, with the most recent appearance on July 3 [3]. Group 3: Financial Performance - For the first half of 2025, Kexing Pharmaceutical reported a revenue of 700 million CNY, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders reached 80.3445 million CNY, reflecting a substantial year-on-year increase of 576.45% [3]. - The company has distributed a total of 51.5446 million CNY in dividends since its A-share listing, with 15.7785 million CNY distributed over the past three years [4]. Group 4: Shareholder Structure - As of June 30, 2025, Kexing Pharmaceutical had 9,412 shareholders, an increase of 16.86% from the previous period, with an average of 21,211 circulating shares per shareholder, a decrease of 14.43% [3]. - Notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which holds 3.669 million shares, and has increased its holdings by 1.6955 million shares [4].

Core Viewpoint - TianKang Biological has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth in the agricultural and livestock sector [1][2]. Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006. The company specializes in the production and sales of biological vaccines for livestock, feed, and plant protein, as well as pig breeding, pig farming, slaughter processing, and meat product sales [1]. - The revenue composition of TianKang Biological includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion yuan, representing a year-on-year growth of 10.68%. The net profit attributable to the parent company was 338 million yuan, reflecting a year-on-year increase of 22.27% [2]. - Since its A-share listing, TianKang Biological has distributed a total of 1.891 billion yuan in dividends, with 598 million yuan distributed over the past three years [3]. Shareholder Information - As of September 10, 2025, the number of shareholders of TianKang Biological was 69,400, an increase of 1.60% from the previous period. The average number of circulating shares per person decreased by 1.57% to 19,672 shares [2]. - Notable institutional shareholders include Guotai Zhongzheng Livestock Breeding ETF, which holds 15.5491 million shares, and Jiashi Agricultural Industry Stock A, holding 10.2945 million shares, both of which have increased their holdings compared to the previous period [3].

Core Viewpoint - The stock price of Kexing Pharmaceutical has shown significant volatility, with a year-to-date increase of 94.21% and recent fluctuations in trading performance [2] Group 1: Stock Performance - As of September 18, Kexing Pharmaceutical's stock rose by 2.03%, reaching 42.30 CNY per share, with a total market capitalization of 8.513 billion CNY [1] - The stock has experienced a 3.50% increase over the last five trading days, a 2.98% decrease over the last 20 days, and a 9.47% increase over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Kexing Pharmaceutical reported a revenue of 700 million CNY, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.3445 million CNY, reflecting a substantial year-on-year increase of 576.45% [2] - Cumulatively, the company has distributed 51.5446 million CNY in dividends since its A-share listing, with 15.7785 million CNY distributed over the past three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2] - The top shareholders include various mutual funds, with notable increases in holdings from E Fund Medical Healthcare Industry Mixed A and other funds [3]

Company Overview - Jinhe Biology Co., Ltd. is located in Inner Mongolia and was established on March 14, 1990, with its listing date on July 13, 2012 [2] - The company specializes in the production, sales, research, and service of animal health products, with a revenue composition of 61.83% from veterinary chemical drugs, 19.76% from starch and related products, 11.12% from veterinary vaccines, 4.97% from environmental services, and 2.15% from other sources [2] Financial Performance - For the first half of 2025, Jinhe Biology achieved a revenue of 1.39 billion yuan, representing a year-on-year growth of 30.45%, and a net profit attributable to shareholders of 138 million yuan, up 51.52% year-on-year [2] - The company has distributed a total of 877 million yuan in dividends since its A-share listing, with 227 million yuan distributed over the past three years [3] Stock Performance - As of September 16, Jinhe Biology's stock price was 7.05 yuan per share, with a market capitalization of 5.44 billion yuan [1] - The stock has increased by 61.22% year-to-date, with a recent 5-day increase of 1.29%, a 20-day decrease of 5.87%, and a 60-day increase of 12.44% [1] - The company has appeared on the trading leaderboard six times this year, with the most recent occurrence on April 16, where it recorded a net buy of -28.30 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 104.38% to 64,500, while the average circulating shares per person decreased by 51.07% to 11,547 shares [2] - Among the top ten circulating shareholders, Guotai Zhongzheng Livestock Breeding ETF is the third-largest shareholder, holding 7.66 million shares as a new investor [3]

Company Overview - Tianbang Food Co., Ltd. is located in Minhang District, Shanghai, and was established on September 25, 1996. The company was listed on April 3, 2007. Its main business involves pig farming and pork product processing [1] - The revenue composition of Tianbang Food includes 63.82% from pig farming, 33.25% from food processing, 2.85% from feed products, and 0.08% from other sources [1] Stock Performance - As of September 16, Tianbang Food's stock price decreased by 2.18%, trading at 3.14 CNY per share, with a total market capitalization of 6.977 billion CNY [1] - Year-to-date, the stock price has increased by 12.54%, with a 1.95% rise over the last five trading days, 4.67% over the last 20 days, and 6.08% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on May 8, where it recorded a net purchase of 20.5299 million CNY [1] Financial Performance - For the first half of 2025, Tianbang Food achieved a revenue of 4.693 billion CNY, representing a year-on-year growth of 8.69%. However, the net profit attributable to shareholders decreased by 58.14% to 352 million CNY [2] - The company has distributed a total of 1.185 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Information - As of September 10, Tianbang Food had 80,800 shareholders, an increase of 0.33% from the previous period. The average number of tradable shares per shareholder is 24,415, which has decreased by 0.33% [2]

Core Insights - The animal vaccine sector saw a rise of 1.30%, ranking 9th among concept sectors, with 14 stocks increasing in value, led by TianKang Biological, BioShares, and Jinhe Biological, which rose by 8.20%, 7.17%, and 3.00% respectively [1][2] - The sector experienced a net inflow of 190 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow, led by Hengtong Co. with 71.08 million yuan [2][3] Sector Performance - The animal vaccine sector's performance was highlighted by the following stocks: - Hengtong Co.: 2.41% increase, 4.20% turnover rate, 71.08 million yuan net inflow, 15.05% net inflow ratio - Jinhe Biological: 3.00% increase, 5.44% turnover rate, 30.31 million yuan net inflow, 10.35% net inflow ratio - Kanghua Biological: 2.14% increase, 4.54% turnover rate, 44.90 million yuan net inflow, 10.14% net inflow ratio [3][4] Stock Movements - The top gainers in the animal vaccine sector included: - TianKang Biological: 8.20% increase - BioShares: 7.17% increase - The stocks with the largest declines included: - Shenlian Biological: 1.51% decrease - Dongfang Biological: 1.31% decrease - Xianfeng Holdings: 1.24% decrease [1][4]

Core Viewpoint - The stock price of Kexing Pharmaceutical has shown significant volatility, with a year-to-date increase of 91.68%, but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 12, Kexing Pharmaceutical's stock price rose by 2.15% to 41.75 CNY per share, with a trading volume of 1.22 billion CNY and a market capitalization of 8.402 billion CNY [1] - The stock has experienced a decline of 1.23% over the last five trading days and 6.45% over the last twenty trading days, while it has increased by 2.45% over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Kexing Pharmaceutical reported a revenue of 700 million CNY, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 80.3445 million CNY, reflecting a year-on-year increase of 576.45% [2] - The company has distributed a total of 51.5446 million CNY in dividends since its A-share listing, with 15.7785 million CNY distributed in the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 16.86% to 9,412, while the average circulating shares per person decreased by 14.43% to 21,211 shares [2] - The top shareholders include E Fund Medical Healthcare Industry Mixed A, which increased its holdings by 1.6955 million shares, and other funds that have also adjusted their positions [3]

Company Overview - Pulaike Bioengineering Co., Ltd. is located in Luoyang, Henan Province, established on June 22, 2002, and listed on May 18, 2015. The company primarily engages in the research, production, sales, and related technology transfer of veterinary biological products, chemical drugs, and traditional veterinary medicine [1][2]. Financial Performance - For the first half of 2025, Pulaike achieved operating revenue of 559 million yuan, representing a year-on-year growth of 15.79%. The net profit attributable to the parent company was 116 million yuan, reflecting a significant increase of 57.12% [2]. - Since its A-share listing, Pulaike has distributed a total of 1.057 billion yuan in dividends, with 500 million yuan distributed over the past three years [3]. Stock Performance - As of September 8, Pulaike's stock price increased by 2.01% to 14.74 yuan per share, with a total market capitalization of 5.101 billion yuan. The stock has risen by 19.21% year-to-date, but has seen a decline of 3.41% over the past 20 days [1]. - The stock's trading volume on September 8 was 27.6557 million yuan, with a turnover rate of 0.55% [1]. Shareholder Information - As of June 30, 2025, Pulaike had 18,000 shareholders, an increase of 4.27% from the previous period. The average number of circulating shares per shareholder was 19,234, which decreased by 4.09% [2]. - Among the top ten circulating shareholders, the Guotai Zhongzheng Livestock Breeding ETF ranked as the seventh largest, holding 3.4499 million shares, an increase of 141,400 shares compared to the previous period [3]. Business Segmentation - The company's main revenue sources include poultry vaccines and antibodies (41.19%), pig vaccines (32.25%), chemical drugs (21.37%), functional health products (1.79%), and pet vaccines (1.38%). Other income sources include technology licensing (0.94%) and vaccines for ruminants (0.25%) [1].

Core Viewpoint - The stock price of Wens Foodstuff Group Co., Ltd. has shown a year-to-date increase of 7.23%, but has recently experienced a decline in the short term, with a 3.42% drop over the last five trading days [2]. Company Overview - Wens Foodstuff Group, established on July 26, 1993, and listed on November 2, 2015, is primarily engaged in the breeding and sales of meat chickens and pigs, with its main revenue sources being 61.85% from pork, 34.06% from chicken, and minor contributions from other segments [2]. - As of June 30, 2025, the company reported a total revenue of 49.875 billion yuan, reflecting a year-on-year growth of 6.67%, and a net profit attributable to shareholders of 3.475 billion yuan, marking a significant increase of 161.77% [2]. Stock Performance and Trading Activity - On September 3, the stock price fell by 2.02% to 17.49 yuan per share, with a trading volume of 6.52 billion yuan and a turnover rate of 0.62%, resulting in a total market capitalization of 116.377 billion yuan [1]. - The net outflow of main funds was 28.8574 million yuan, with large orders showing a buy of 143 million yuan and a sell of 137 million yuan, indicating mixed trading activity [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 20.62% to 91,000, while the average circulating shares per person increased by 43.71% to 65,602 shares [2]. - The company has distributed a total of 28.116 billion yuan in dividends since its A-share listing, with 4.942 billion yuan distributed over the past three years [3]. Institutional Holdings - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 139 million shares, an increase of 20.044 million shares from the previous period, while E Fund's ChiNext ETF has reduced its holdings by 5.625 million shares [3].

Core Viewpoint - TianKang Biological has shown significant growth in its performance for the first half of the year, with notable increases in revenue and profit metrics, despite mixed results across different business segments [2]. Financial Performance - The company achieved an operating revenue of 8.847 billion, a year-on-year increase of 10.68% [2] - Total profit reached 421 million, reflecting a year-on-year growth of 43.29% [2] - Net profit attributable to shareholders was 338 million, up 22.27% year-on-year [2] - Net profit excluding non-recurring gains and losses was 314 million, an increase of 16.17% year-on-year [2] Business Segment Performance - Feed business sales volume was 134.15 thousand tons, with sales revenue of 2.434 billion, a decline of 14.24% year-on-year [2] - Pig sales reached 1.5282 million heads, a growth of 9.05%, with sales revenue of 2.849 billion, down 0.95% year-on-year [2] - Animal vaccine business sales revenue was 482 million, with growth details not specified [2] - Protein oil business sales revenue was 1.449 billion, showing a significant increase of 97.60% year-on-year [2] - Corn storage business sales revenue was 1.305 billion, up 72.32% year-on-year [2] Cost Management and Strategic Developments - Self-breeding costs decreased to 12.55 per kilogram, with potential for further reduction as piglet prices decline [3] - The company is in the process of acquiring Qiangdu Livestock, which has shown strong operational performance and cost competitiveness [3] - The protein oil business has seen a significant increase in profitability, with a recent joint venture contributing positively [3] - The corn storage business has turned profitable after a period of losses, with expectations for continued good performance [3] - TianKang Pharmaceutical's listing progress is ongoing, with recent inquiries and updates planned [3]